Keler T - Search Results

1

Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies.

Korman A, Yellin M, Keler T. Korman A, et al. Among authors: keler t. Curr Opin Investig Drugs. 2005 Jun;6(6):582-91. Curr Opin Investig Drugs. 2005. PMID: 15988909 Review.

2

Construction and characterization of a humanized anti-gamma-Ig receptor type I (Fc gamma RI) monoclonal antibody.

Graziano RF, Tempest PR, White P, Keler T, Deo Y, Ghebremariam H, Coleman K, Pfefferkorn LC, Fanger MW, Guyre PM. Graziano RF, et al. Among authors: keler t. J Immunol. 1995 Nov 15;155(10):4996-5002. J Immunol. 1995. PMID: 7594506

3

Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells.

Keler T, Graziano RF, Mandal A, Wallace PK, Fisher J, Guyre PM, Fanger MW, Deo YM. Keler T, et al. Cancer Res. 1997 Sep 15;57(18):4008-14. Cancer Res. 1997. PMID: 9307286

4

Characterization of a novel bispecific antibody that mediates Fcgamma receptor type I-dependent killing of tumor-associated glycoprotein-72-expressing tumor cells.

Russoniello C, Somasundaram C, Schlom J, Deo YM, Keler T. Russoniello C, et al. Among authors: keler t. Clin Cancer Res. 1998 Sep;4(9):2237-43. Clin Cancer Res. 1998. PMID: 9748144

5

Development of a trispecific antibody conjugate that directs two distinct tumor-associated antigens to CD64 on myeloid effector cells.

Somasundaram C, Sundarapandiyan K, Keler T, Deo YM, Graziano RF. Somasundaram C, et al. Among authors: keler t. Hum Antibodies. 1999;9(1):47-54. Hum Antibodies. 1999. PMID: 10331185

6

Targeting weak antigens to CD64 elicits potent humoral responses in human CD64 transgenic mice.

Keler T, Guyre PM, Vitale LA, Sundarapandiyan K, van De Winkel JG, Deo YM, Graziano RF. Keler T, et al. J Immunol. 2000 Dec 15;165(12):6738-42. doi: 10.4049/jimmunol.165.12.6738. J Immunol. 2000. PMID: 11120792

7

Bispecific antibody-mediated destruction of Hodgkin's lymphoma cells.

Sundarapandiyan K, Keler T, Behnke D, Engert A, Barth S, Matthey B, Deo YM, Graziano RF. Sundarapandiyan K, et al. Among authors: keler t. J Immunol Methods. 2001 Feb 1;248(1-2):113-23. doi: 10.1016/s0022-1759(00)00347-1. J Immunol Methods. 2001. PMID: 11223073

8

Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques.

Keler T, Halk E, Vitale L, O'Neill T, Blanset D, Lee S, Srinivasan M, Graziano RF, Davis T, Lonberg N, Korman A. Keler T, et al. J Immunol. 2003 Dec 1;171(11):6251-9. doi: 10.4049/jimmunol.171.11.6251. J Immunol. 2003. PMID: 14634142

9

Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules.

Ramakrishna V, Treml JF, Vitale L, Connolly JE, O'Neill T, Smith PA, Jones CL, He LZ, Goldstein J, Wallace PK, Keler T, Endres MJ. Ramakrishna V, et al. Among authors: keler t. J Immunol. 2004 Mar 1;172(5):2845-52. doi: 10.4049/jimmunol.172.5.2845. J Immunol. 2004. PMID: 14978085

10

A novel human cancer vaccine elicits cellular responses to the tumor-associated antigen, human chorionic gonadotropin beta.

He LZ, Ramakrishna V, Connolly JE, Wang XT, Smith PA, Jones CL, Valkova-Valchanova M, Arunakumari A, Treml JF, Goldstein J, Wallace PK, Keler T, Endres MJ. He LZ, et al. Among authors: keler t. Clin Cancer Res. 2004 Mar 15;10(6):1920-7. doi: 10.1158/1078-0432.ccr-03-0264. Clin Cancer Res. 2004. PMID: 15041707

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results